Clinical Trial Update: A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates the safety and immunogenicity of the epitope-based DNA vaccine EP HIV-1090 in HIV-1 infected individuals receiving antiretroviral t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• EP HIV-1090

Snippet

Sponsor: Epimmune | Conditions: HIV Infections | Phase 1 | Status: UNKNOWN